Study on the effect of TP chemotherapy regimen combined with Qinggong detoxification soup on the clinical efficacy of cervical cancer patients

The main objective of this study is to check the efficacy of the combinational chemother-apy regimen and Qing Gong Detoxification Soup on the epithelial-mesenchymal transition gene expression, immune homeostasis mechanism, and tumor markers in patients with cervical cancer. In the present study, 88 individuals with cervical cancer were selected as experimental and control groups, 44 cases each, using the random number table method. The clinical efficacy, expression of epithelial-mesenchymal transition genes (Vimentin, N-cadherin, E-cadherin, α-catenin), Th1/Th2 (T helper cell 1/T helper cell 2), cytokines (IFN-γ, IL-4, IL-2, IL-6), tumor markers (CEA, SCCA, CA125), TCM (Traditional Chinese Medicine) symptom score and adverse reactions were investigated throughout the entire study. Our results clearly indicated the significant effectiveness of our combinational therapy in the treatment of cancer by 84.09% in comparison to the control group (63.64%). No significant differences in the primary and secondary symptom scores; i.e., IFN-γ (Interferon-gamma), IL-2 (Interleukin-2), IL-4 (Interleukin-4), IL-6 (Interleukin-6), CEA (carcinoembryonic antigen), SCCA (squamous cell carcinoma antigen), and expression of several epithelial-mesenchymal transition genes, IFN-γ, as well as IL-2 between experimental and control groups were observed before starting the therapy. IFN-γ, IL-2, IL-4, IL-6, CEA, SCCA and CA125 (cancer antigen 125) scores were significantly improved after treatment in both groups, although the study group outperformed the control group and the differences were statistically significant (p < 0.05). We also found that the incidence of adverse reactions was 9.09% in the experimental group which was lower than 25.00% in the control group, and the differences were statistically significant (p < 0.05). This study confirmed that combinational therapy of Qing Gong Detoxification Soup and TP (paclitaxel-cisplatin) chemotherapy significantly enhanced the expression of the epithelial-mesenchymal transformation gene, repaired immune homeostasis, inhibited tumor markers, and reduced the occurrence of adverse reactions.

Qing gong detoxification soup; Cervical cancer; Epithelial-mesenchymal transition gene expression; Immune homeostasis; Tumor markers

[1] Zheng JJ, Miao JR, Wu Q, Yu CX, Mu L, Song JH. Correlation between HPV-negative cervical lesions and cervical microenvironment. Taiwanese Journal of Obstetrics & Gynecology. 2020; 59: 855–861.

[2] Jansen EEL, de Kok IMCM, Kaljouw S, Demirel E, de Koning HJ, Hontelez JAC. Rapid elimination of cervical cancer while maintaining the harms and benefits ratio of cervical cancer screening: a modelling study. BMC Medicine. 2022; 20: 433.

[3] Nygård M, Hansen BT, Kjaer SK, Hortlund M, Tryggvadóttir L, Munk C, et al. Human papillomavirus genotype-specific risks for cervical intraepithelial lesions. Human Vaccines & Immunotherapeutics. 2021; 17: 972–981.

[4] Zhang Y, Yu M, Jing Y, Cheng J, Zhang C, Cheng L, et al. Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer. British Journal of Cancer. 2021; 124: 41–424.

[5] Glenn BA, Nonzee NJ, Tieu L, Pedone B, Cowgill BO, Bastani R. Human papillomavirus (HPV) vaccination in the transition between adolescence and adulthood. Vaccine. 2021; 39: 3435–3444.

[6] Li ZG, Chen JH, Zhao SB, Li YJ, Zhou J, Liang JH, et al. Discovery and validation of novel biomarkers for detection of cervical cancer. Cancer Medicine. 2021; 10: 2063–2074.

[7] Nie Y, Liu DD, Yang W, Li YZ, Zhang LH, Cheng X, et al. Increased expression of TIGIT and KLRG1 correlates with impaired CD56bright NK cell immunity in HPV16-related cervical intraepithelial neoplasia. Virology Journal. 2022; 19: 68.

[8] Cararo-Lopes E, Dias MH, da Silva MS, Zeidler JD, Vessoni AT, Reis MS, et al. Autophagy buffers Ras-induced genotoxic stress enabling malignant transformation in keratinocytes primed by human papillomavirus. Cell Death & Disease. 2021; 12: 194.

[9] Bi D, Apter D, Eriksson T, Hokkanen M, Zima J, Damaso S, et al. Safety of the as04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12–15 years: end-of-study results from a community-randomized study up to 6.5 years. Human Vaccines & Immunotherapeutics. 2020; 16: 1392–1403.

[10] Jayarajah U, Abeygunasekera AM. Cancer services in Sri Lanka: current status and future directions. Journal of the Egyptian National Cancer Institute. 2021; 33: 13.

[11] Chyderiotis S, Sicsic J, Raude J, Bonmarin I, Jeanleboeuf F, Le Duc Banaszuk A, et al. Optimising HPV vaccination communication to adolescents: a discrete choice experiment. Vaccine. 2021; 39: 3916–3925.

[12] Ahmed S, Khan H, Fakhri S, Aschner M, Cheang WS. Therapeutic potential of marine peptides in cervical and ovarian cancers. Molecular and Cellular Biochemistry. 2022; 477: 605–619.

[13] Lum C, Prenen H, Body A, Lam M, Segelov E. A 2020 update of anal cancer: the increasing problem in women and expanding treatment landscape. Expert Review of Gastroenterology & Hepatology. 2020; 14: 665–680.

[14] Matsumoto T, Matsumaru N, Scuffham P, Neels P, Tsukamoto K. Alternative new mono-scaled quantitative benefit–risk assessment of human papillomavirus vaccine in Japan. Therapeutic Innovation & Regulatory Science. 2021; 55: 48–55.

[15] Lawal IK, Suleiman AK, Bagudu Z, Kanmodi KK, Abdulsalam GA, Olakunle OS. Planning and advocating for cervical cancer prevention in Kebbi State, Nigeria: learning points for the global call to eliminate cervical cancer. International Journal of Gynecology & Obstetrics. 2021; 152: 26–31.

[16] Murall CL, Reyné B, Selinger C, Bernat C, Boué V, Grasset S, et al. HPV cervical infections and serological status in vaccinated and unvaccinated women. Vaccine. 2020; 38: 8167–8174.

[17] Xu T, Zeng YL, Shi LL, Yang Q, Chen YS, Wu G, et al. Targeting NEK2 impairs oncogenesis and radioresistance via inhibiting the Wnt1/beta-catenin signaling pathway in cervical cancer. Journal of Experimental & Clinical Cancer Research. 2020; 39: 183.

[18] Nayar R, Chhieng DC, Crothers B, Darragh TM, Davey DD, Eisenhut C, et al. Moving forward—the 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors and beyond: implications and suggestions for laboratories. Journal of the American Society of Cytopathology. 2020; 9: 291–303.